Alfred Sorbello, Syed Arefinul Haque, Rashedul Hasan, Richard Jermyn, Ahmad Hussein, Alex Vega, Krzysztof Zembrzuski, Anna Ripple, Mitra Ahadpour
{"title":"从电子健康记录中告知阿片类药物警戒的人工智能软件原型:开发和可用性研究。","authors":"Alfred Sorbello, Syed Arefinul Haque, Rashedul Hasan, Richard Jermyn, Ahmad Hussein, Alex Vega, Krzysztof Zembrzuski, Anna Ripple, Mitra Ahadpour","doi":"10.2196/45000","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The use of patient health and treatment information captured in structured and unstructured formats in computerized electronic health record (EHR) repositories could potentially augment the detection of safety signals for drug products regulated by the US Food and Drug Administration (FDA). Natural language processing and other artificial intelligence (AI) techniques provide novel methodologies that could be leveraged to extract clinically useful information from EHR resources.</p><p><strong>Objective: </strong>Our aim is to develop a novel AI-enabled software prototype to identify adverse drug event (ADE) safety signals from free-text discharge summaries in EHRs to enhance opioid drug safety and research activities at the FDA.</p><p><strong>Methods: </strong>We developed a prototype for web-based software that leverages keyword and trigger-phrase searching with rule-based algorithms and deep learning to extract candidate ADEs for specific opioid drugs from discharge summaries in the Medical Information Mart for Intensive Care III (MIMIC III) database. The prototype uses MedSpacy components to identify relevant sections of discharge summaries and a pretrained natural language processing (NLP) model, Spark NLP for Healthcare, for named entity recognition. Fifteen FDA staff members provided feedback on the prototype's features and functionalities.</p><p><strong>Results: </strong>Using the prototype, we were able to identify known, labeled, opioid-related adverse drug reactions from text in EHRs. The AI-enabled model achieved accuracy, recall, precision, and <i>F</i><sub>1</sub>-scores of 0.66, 0.69, 0.64, and 0.67, respectively. FDA participants assessed the prototype as highly desirable in user satisfaction, visualizations, and in the potential to support drug safety signal detection for opioid drugs from EHR data while saving time and manual effort. Actionable design recommendations included (1) enlarging the tabs and visualizations; (2) enabling more flexibility and customizations to fit end users' individual needs; (3) providing additional instructional resources; (4) adding multiple graph export functionality; and (5) adding project summaries.</p><p><strong>Conclusions: </strong>The novel prototype uses innovative AI-based techniques to automate searching for, extracting, and analyzing clinically useful information captured in unstructured text in EHRs. It increases efficiency in harnessing real-world data for opioid drug safety and increases the usability of the data to support regulatory review while decreasing the manual research burden.</p>","PeriodicalId":73551,"journal":{"name":"JMIR AI","volume":"2 ","pages":"e45000"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538589/pdf/","citationCount":"0","resultStr":"{\"title\":\"Artificial Intelligence-Enabled Software Prototype to Inform Opioid Pharmacovigilance From Electronic Health Records: Development and Usability Study.\",\"authors\":\"Alfred Sorbello, Syed Arefinul Haque, Rashedul Hasan, Richard Jermyn, Ahmad Hussein, Alex Vega, Krzysztof Zembrzuski, Anna Ripple, Mitra Ahadpour\",\"doi\":\"10.2196/45000\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The use of patient health and treatment information captured in structured and unstructured formats in computerized electronic health record (EHR) repositories could potentially augment the detection of safety signals for drug products regulated by the US Food and Drug Administration (FDA). Natural language processing and other artificial intelligence (AI) techniques provide novel methodologies that could be leveraged to extract clinically useful information from EHR resources.</p><p><strong>Objective: </strong>Our aim is to develop a novel AI-enabled software prototype to identify adverse drug event (ADE) safety signals from free-text discharge summaries in EHRs to enhance opioid drug safety and research activities at the FDA.</p><p><strong>Methods: </strong>We developed a prototype for web-based software that leverages keyword and trigger-phrase searching with rule-based algorithms and deep learning to extract candidate ADEs for specific opioid drugs from discharge summaries in the Medical Information Mart for Intensive Care III (MIMIC III) database. The prototype uses MedSpacy components to identify relevant sections of discharge summaries and a pretrained natural language processing (NLP) model, Spark NLP for Healthcare, for named entity recognition. Fifteen FDA staff members provided feedback on the prototype's features and functionalities.</p><p><strong>Results: </strong>Using the prototype, we were able to identify known, labeled, opioid-related adverse drug reactions from text in EHRs. The AI-enabled model achieved accuracy, recall, precision, and <i>F</i><sub>1</sub>-scores of 0.66, 0.69, 0.64, and 0.67, respectively. FDA participants assessed the prototype as highly desirable in user satisfaction, visualizations, and in the potential to support drug safety signal detection for opioid drugs from EHR data while saving time and manual effort. Actionable design recommendations included (1) enlarging the tabs and visualizations; (2) enabling more flexibility and customizations to fit end users' individual needs; (3) providing additional instructional resources; (4) adding multiple graph export functionality; and (5) adding project summaries.</p><p><strong>Conclusions: </strong>The novel prototype uses innovative AI-based techniques to automate searching for, extracting, and analyzing clinically useful information captured in unstructured text in EHRs. It increases efficiency in harnessing real-world data for opioid drug safety and increases the usability of the data to support regulatory review while decreasing the manual research burden.</p>\",\"PeriodicalId\":73551,\"journal\":{\"name\":\"JMIR AI\",\"volume\":\"2 \",\"pages\":\"e45000\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538589/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JMIR AI\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2196/45000\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMIR AI","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/45000","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/18 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:在计算机化电子健康记录(EHR)存储库中使用以结构化和非结构化格式捕获的患者健康和治疗信息,可能会增强对美国食品药品监督管理局(FDA)监管的药品安全信号的检测。自然语言处理和其他人工智能(AI)技术提供了新的方法,可以用来从EHR资源中提取临床有用的信息。目的:我们的目标是开发一种新的人工智能软件原型,从EHR中的自由文本出院摘要中识别不良药物事件(ADE)安全信号,以增强阿片类药物的安全性和美国食品药品监督管理局的研究活动。方法:我们开发了一个基于网络的软件原型,该软件利用基于规则的算法和深度学习的关键词和触发短语搜索来提取重症监护医疗信息集市III(MIMIC III)数据库出院总结中特定阿片类药物的候选ADE。原型使用MedSpacy组件来识别出院摘要的相关部分,并使用预训练的自然语言处理(NLP)模型Spark NLP for Healthcare进行命名实体识别。15名美国食品药品监督管理局工作人员就原型的特点和功能提供了反馈。结果:使用该原型,我们能够从EHRs中的文本中识别已知的、标记的阿片类药物相关不良反应。人工智能模型的准确度、召回率、精确度和F1得分分别为0.66、0.69、0.64和0.67。美国食品药品监督管理局的参与者评估该原型在用户满意度、可视化以及支持从EHR数据中检测阿片类药物的药物安全信号的潜力方面非常理想,同时节省了时间和人力。可操作的设计建议包括:(1)扩大标签和可视化;(2) 实现更大的灵活性和定制,以满足最终用户的个人需求;(3) 提供额外的教学资源;(4) 添加多个图形导出功能;(5)增加项目摘要。结论:新的原型使用创新的基于人工智能的技术来自动搜索、提取和分析EHR中非结构化文本中捕获的临床有用信息。它提高了利用真实世界的阿片类药物安全数据的效率,并增加了数据的可用性,以支持监管审查,同时减少了手动研究负担。
Artificial Intelligence-Enabled Software Prototype to Inform Opioid Pharmacovigilance From Electronic Health Records: Development and Usability Study.
Background: The use of patient health and treatment information captured in structured and unstructured formats in computerized electronic health record (EHR) repositories could potentially augment the detection of safety signals for drug products regulated by the US Food and Drug Administration (FDA). Natural language processing and other artificial intelligence (AI) techniques provide novel methodologies that could be leveraged to extract clinically useful information from EHR resources.
Objective: Our aim is to develop a novel AI-enabled software prototype to identify adverse drug event (ADE) safety signals from free-text discharge summaries in EHRs to enhance opioid drug safety and research activities at the FDA.
Methods: We developed a prototype for web-based software that leverages keyword and trigger-phrase searching with rule-based algorithms and deep learning to extract candidate ADEs for specific opioid drugs from discharge summaries in the Medical Information Mart for Intensive Care III (MIMIC III) database. The prototype uses MedSpacy components to identify relevant sections of discharge summaries and a pretrained natural language processing (NLP) model, Spark NLP for Healthcare, for named entity recognition. Fifteen FDA staff members provided feedback on the prototype's features and functionalities.
Results: Using the prototype, we were able to identify known, labeled, opioid-related adverse drug reactions from text in EHRs. The AI-enabled model achieved accuracy, recall, precision, and F1-scores of 0.66, 0.69, 0.64, and 0.67, respectively. FDA participants assessed the prototype as highly desirable in user satisfaction, visualizations, and in the potential to support drug safety signal detection for opioid drugs from EHR data while saving time and manual effort. Actionable design recommendations included (1) enlarging the tabs and visualizations; (2) enabling more flexibility and customizations to fit end users' individual needs; (3) providing additional instructional resources; (4) adding multiple graph export functionality; and (5) adding project summaries.
Conclusions: The novel prototype uses innovative AI-based techniques to automate searching for, extracting, and analyzing clinically useful information captured in unstructured text in EHRs. It increases efficiency in harnessing real-world data for opioid drug safety and increases the usability of the data to support regulatory review while decreasing the manual research burden.